Driving business growth, operational excellence and regulatory compliance through digital innovation, cost optimization, process transformation and strategic change management.
Our life sciences advisory experts are ready to steer you through the maze of technologies and compliance regulations to develop successful enterprise and digital solutions that best fit your strategic goals and needs of patients. We have expertise in:
With ISG’s life sciences consultants, you can identify opportunities for cost optimization and service quality improvement, design a roadmap to achieve excellence, and establish a platform for substantial and sustained results
AI investment is accelerating, but results remain uneven. Only one in four initiatives is meeting revenue impact expectations, at an average spend of $1.3M per use case. Enterprises are no longer asking whether AI works. They are being asked to prove that it pays.
We help you identify where AI agents deliver the most value, restructure workflows around them and build the accountability models that keep autonomous execution auditable. The enterprises that win won't be the ones that reacted. They'll be the ones that designed for it first.
We give enterprises transparent, benchmarkable pricing models that tag each resource unit with the autonomy level used to deliver it. As AI capability advances, your pricing keeps pace. Both buyers and providers can quantify what that progress is worth.
We bring analysis of more than $2.6 billion in tracked AI spend to every sourcing decision. Procurement, technology and finance leaders get the independent intelligence to rationalize vendor portfolios and hold providers accountable to measurable outcomes.
We embed controls at the point of data creation, define accountability for autonomous actions and build adaptive frameworks that keep pace with AI without impeding it. Enterprises that get this right don't just manage risk. They build the trust that lets them scale faster.
We ground strategy in research across 2,400 enterprise use cases, aligning investment to where impact is proven and designing the data, talent and governance foundations that move AI from pilots into the workflows that drive commercial results.
We benchmark your AI readiness against peers across 75 countries, identify the dimensions holding you back and give you a personalized roadmap to close the gap.
AI investment is shifting decisively toward revenue-generating functions. CRM automation, sales enablement and forecasting have replaced chatbots and IT productivity tools as the leading use case priorities, reflecting enterprise recognition that productivity gains alone do not satisfy board-level scrutiny. At the same time, use cases in production have doubled since 2024, and the portfolio is diversifying rapidly, with over 300 distinct function and industry-specific use cases now in active deployment.
ISG research across 2,400 enterprise use cases shows that the strongest AI returns are currently concentrated in compliance, risk management and quality control, not in the growth and cost outcomes most enterprises originally set out to achieve
The gap between where enterprises are investing and where AI is actually delivering is the defining commercial tension of 2025. Organizations that close it by targeting functions with structured, revenue-attributable data and clear ROI measures will establish performance benchmarks that compress the window for competitors still cycling through pilots. The standard is being set now.
ISG is a leader in proprietary research, advisory consulting and executive event services focused on market trends and disruptive technologies.
Get the insight and guidance you need to accelerate growth and create more value.
Learn MoreThe global medical devices sector is at an inflection point in 2025, where the convergence of technology, regulation and patient expectations is reshaping how products are designed, approved and monitored. The industry is experiencing heightened digital adoption across three critical areas: digital engineering and product development; regulatory compliance, strategy and quality assurance; and post-market digital enablement.
The life sciences industry is undergoing a profound transformation, shaped by digital disruption, patient-first innovation and an unrelenting drive toward operational sustainability. Service providers that lead in this space are moving beyond traditional models by embracing AI, generative AI (GenAI), IoT and advanced analytics to reimagine value delivery across clinical development, manufacturing, commercial operations and patient engagement. At this pivotal juncture, the strategic imperative is clear: those who embed intelligence, interoperability and inclusivity across their value chain will accelerate innovation and redefine outcomes.
The advances in data, analytics, Generative AI (GenAI) and agentic AI are transforming how healthcare and life sciences (HCLS) organizations deliver care, accelerate research, manage operations and engage patients. These innovations are driving measurable improvements in efficiency, accuracy and patient outcomes; however, adoption is not without challenges. Regulatory complexity, talent shortages, operational pressures and the need for responsible AI use demand thoughtful strategies. Organizations that can simultaneously innovate, scale responsibly and work closely with analytics partners to translate analytics goals into tangible outcomes will be the ones to succeed.
The clinical trials landscape is undergoing a significant transformation with the rise of decentralized trial methodologies. A growing recognition of the limitations of traditional trial approaches, such as centralized site-based monitoring and patient visits, drives this shift. Decentralized trials offer a promising alternative by leveraging digital technologies to conduct certain trial activities remotely, including patient recruitment, consent, data collection and monitoring. This approach enhances patient convenience and participation and enables real-time data collection and analysis, leading to more efficient and cost-effective trials.
In the past year, as the world continued to recover from the challenges and restrictions implemented to manage the COVID-19 situation, leading life science companies and the providers that support them made significant advances in incorporating technology solutions into the DNA of their operations. This sector has historically been reluctant to embrace innovative approaches at scale, but the pandemic has catalyzed a permanent change. For starters, the pandemic made many formerly standard processes, such as in-person patient visits and justin- time supply chain practices impossible, which created an unprecedented demand for innovative solutions. Leading solution providers not only intervened with existing technology solutions but also demonstrated their readiness to collaborate, innovate and invest with greater flexibility and customer-centric focus than ever before.
